Tengion to Host Conference Call to Provide a Business Update and Report Third Quarter 2012 Financial Results on November 13, 2012

WINSTON-SALEM, N.C., Nov. 6, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Tuesday, November 13, 2012, at 8:30 a.m. EST to provide a business update and discuss its third quarter 2012 financial results.

To participate in the call, please dial 866-800-8651 (domestic) or 617-614-2704 (international) and reference access code 64284960.

The conference call can be accessed from the Investors section of the Company's website at www.tengion.com or directly at http://www.media-server.com/m/p/6pr35s84. The webcast will also be archived on the website.

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

SOURCE Tengion, Inc.

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.